Table 2.

Endpoints of the study

	Patient-reported outcomes	Partners-reported outcomes	Physician-reported outcomes	Patient-reported and physician-reported outcomes
Primary endpoint	WHO-5
Secondary endpoint	DLQI-R TSQM-9 PBI-S-10 WPAI: PSO Patient grid NRS (itch, pain, joint pain, fatigue assessments) Sociodemographic and clinical characteristics AEs during tildrakizumab use	FamilyPso	Physicians’ satisfaction Absolute PASI
Exploratory endpoints			PGA	Patient’s and physician’s questionnaire Patient’s and physician’s satisfaction of being part of the study

AEs, adverse events; DLQI-R, Dermatology Life Quality Index-Revised; NRS, Numeric Rating Scale; PASI, Psoriasis Area Severity Index; PBI-S-10, Patient Benefit Index 'Standard', 10 items short form; PGA, Physician Global Assessment; TSQM-9, Treatment Satisfaction Questionnaire for Medication; WHO-5, World Health Organization-Five Well-being Index; WPAI:PSO, Work Productivity and Activity Impairment Questionnaire: Psoriasis.